Cargando…
Targets of statins intervention in LDL-C metabolism: Gut microbiota
Increasing researches have considered gut microbiota as a new “metabolic organ,” which mediates the occurrence and development of metabolic diseases. In addition, the liver is an important organ of lipid metabolism, and abnormal lipid metabolism can cause the elevation of blood lipids. Among them, e...
Autores principales: | Sun, ChangXin, Wang, ZePing, Hu, LanQing, Zhang, XiaoNan, Chen, JiYe, Yu, ZongLiang, Liu, LongTao, Wu, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492915/ https://www.ncbi.nlm.nih.gov/pubmed/36158845 http://dx.doi.org/10.3389/fcvm.2022.972603 |
Ejemplares similares
-
Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview
por: Wu, Min, et al.
Publicado: (2021) -
Protective effects of paeoniflorin on cardiovascular diseases: A pharmacological and mechanistic overview
por: Li, Xiaoya, et al.
Publicado: (2023) -
Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022) -
Gut Microbiota and Atherosclerosis—Focusing on the Plaque Stability
por: Shen, Xinyi, et al.
Publicado: (2021) -
The gut microbiota in experimental abdominal aortic aneurysm
por: Xiao, Jie, et al.
Publicado: (2023)